GTBIF
Price
$8.27
Change
+$0.36 (+4.55%)
Updated
Sep 5 closing price
Capitalization
1.92B
ORGO
Price
$5.00
Change
-$0.03 (-0.60%)
Updated
Sep 5 closing price
Capitalization
634.29M
60 days until earnings call
Interact to see
Advertisement

GTBIF vs ORGO

Header iconGTBIF vs ORGO Comparison
Open Charts GTBIF vs ORGOBanner chart's image
Green Thumb Industries
Price$8.27
Change+$0.36 (+4.55%)
Volume$211.33K
Capitalization1.92B
Organogenesis Holdings
Price$5.00
Change-$0.03 (-0.60%)
Volume$402.52K
Capitalization634.29M
GTBIF vs ORGO Comparison Chart in %
Loading...
GTBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GTBIF vs. ORGO commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTBIF is a Hold and ORGO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (GTBIF: $8.27 vs. ORGO: $5.00)
Brand notoriety: GTBIF and ORGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: GTBIF: 29% vs. ORGO: 50%
Market capitalization -- GTBIF: $1.92B vs. ORGO: $634.29M
GTBIF [@Pharmaceuticals: Generic] is valued at $1.92B. ORGO’s [@Pharmaceuticals: Generic] market capitalization is $634.29M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GTBIF’s FA Score shows that 1 FA rating(s) are green whileORGO’s FA Score has 1 green FA rating(s).

  • GTBIF’s FA Score: 1 green, 4 red.
  • ORGO’s FA Score: 1 green, 4 red.
According to our system of comparison, both GTBIF and ORGO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GTBIF’s TA Score shows that 4 TA indicator(s) are bullish while ORGO’s TA Score has 5 bullish TA indicator(s).

  • GTBIF’s TA Score: 4 bullish, 5 bearish.
  • ORGO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ORGO is a better buy in the short-term than GTBIF.

Price Growth

GTBIF (@Pharmaceuticals: Generic) experienced а -4.83% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was -2.91% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

ORGO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GTBIF($1.92B) has a higher market cap than ORGO($634M). GTBIF has higher P/E ratio than ORGO: GTBIF (75.18) vs ORGO (63.75). ORGO YTD gains are higher at: 56.250 vs. GTBIF (1.224). GTBIF has higher annual earnings (EBITDA): 338M vs. ORGO (3.19M). GTBIF has more cash in the bank: 177M vs. ORGO (73.1M). ORGO has less debt than GTBIF: ORGO (40.8M) vs GTBIF (523M). GTBIF has higher revenues than ORGO: GTBIF (1.15B) vs ORGO (429M).
GTBIFORGOGTBIF / ORGO
Capitalization1.92B634M303%
EBITDA338M3.19M10,592%
Gain YTD1.22456.2502%
P/E Ratio75.1863.75118%
Revenue1.15B429M269%
Total Cash177M73.1M242%
Total Debt523M40.8M1,282%
FUNDAMENTALS RATINGS
GTBIF vs ORGO: Fundamental Ratings
GTBIF
ORGO
OUTLOOK RATING
1..100
6921
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9195
PRICE GROWTH RATING
1..100
4339
P/E GROWTH RATING
1..100
911
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (75) in the Financial Conglomerates industry is in the same range as GTBIF (85) in the null industry. This means that ORGO’s stock grew similarly to GTBIF’s over the last 12 months.

ORGO's Profit vs Risk Rating (94) in the Financial Conglomerates industry is in the same range as GTBIF (100) in the null industry. This means that ORGO’s stock grew similarly to GTBIF’s over the last 12 months.

GTBIF's SMR Rating (91) in the null industry is in the same range as ORGO (95) in the Financial Conglomerates industry. This means that GTBIF’s stock grew similarly to ORGO’s over the last 12 months.

ORGO's Price Growth Rating (39) in the Financial Conglomerates industry is in the same range as GTBIF (43) in the null industry. This means that ORGO’s stock grew similarly to GTBIF’s over the last 12 months.

GTBIF's P/E Growth Rating (9) in the null industry is in the same range as ORGO (11) in the Financial Conglomerates industry. This means that GTBIF’s stock grew similarly to ORGO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GTBIFORGO
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 19 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
GTBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MTRAX22.130.09
+0.41%
NYLI Income Builder Class A
ANFCX57.03N/A
N/A
American Funds New Economy C
TMVAX28.95N/A
N/A
RBC Microcap Value A
ALCEX15.33N/A
N/A
Avantis U.S. Large Cap Value G
AAGPX24.59-0.08
-0.32%
American Beacon Large Cap Value Inv

GTBIF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBIF has been closely correlated with CURLF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if GTBIF jumps, then CURLF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBIF
1D Price
Change %
GTBIF100%
+4.55%
CURLF - GTBIF
82%
Closely correlated
+1.79%
TCNNF - GTBIF
82%
Closely correlated
+4.55%
VRNOF - GTBIF
79%
Closely correlated
+5.51%
TSNDF - GTBIF
77%
Closely correlated
+13.08%
CRLBF - GTBIF
71%
Closely correlated
+5.26%
More

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
-0.60%
ANIP - ORGO
47%
Loosely correlated
-0.68%
PRGO - ORGO
46%
Loosely correlated
-2.75%
ANIK - ORGO
33%
Loosely correlated
-1.65%
AMRX - ORGO
29%
Poorly correlated
+0.73%
GTBIF - ORGO
29%
Poorly correlated
+4.55%
More